Welcome to our dedicated page for Tarsus Pharmaceuticals news (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals stock.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a clinical-stage biopharmaceutical company based in Irvine, California, dedicated to the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Founded in 2016, Tarsus stands at the forefront of eye care innovation with a mission to revolutionize treatments for patients by addressing unmet needs through proven science and new technology.
The company’s flagship product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, was approved by the FDA in 2023. XDEMVY is a pioneering eye drop designed to treat Demodex blepharitis, a common eyelid inflammation caused by an infestation of Demodex mites. Clinical trials involving more than 800 patients demonstrated its efficacy, meeting primary and secondary endpoints with no serious treatment-related adverse events.
Beyond XDEMVY, Tarsus is advancing a diverse pipeline of therapeutic candidates. TP-03 is under investigation for the treatment of Meibomian Gland Disease (MGD), a condition often comorbid with Demodex infestation. TP-04 is being developed for the treatment of papulopustular rosacea (PPR), while TP-05 is explored as a groundbreaking oral prophylactic for Lyme disease and community malaria reduction.
The company’s recent achievements underscore its commitment to advancing therapeutic options in ophthalmology and beyond. Tarsus reported significant clinical improvements in MGD with TP-03, highlighting its potential to address underlying causes of the disease. Additionally, TP-05 showed promising results in early trials, demonstrating high tick mortality rates and suggesting potential as an on-demand prophylactic against Lyme disease.
Tarsus Pharmaceuticals collaborates with leading institutions like Tufts University School of Medicine to bolster its research endeavors. The company is also gaining traction in the marketplace, evidenced by strong quarterly financial results and strategic partnerships with major investment firms such as Goldman Sachs, BofA Securities, and Guggenheim Securities.
With ongoing consumer awareness campaigns such as “Mite Party” for XDEMVY, Tarsus is actively engaging patients and healthcare providers to improve diagnosis and treatment outcomes for Demodex blepharitis. This multi-channel initiative aims to educate the public about the prevalence and impact of Demodex infestation, encouraging patients to seek professional care.
Committed to patient-centric innovation, Tarsus Pharmaceuticals continues to expand its footprint in eye care and explore new therapeutic frontiers, striving to make a significant impact on public health through scientifically driven solutions.
Tarsus Pharmaceuticals (NASDAQ: TARS) has appointed Rosemary A. Crane to its Board of Directors, where she will chair the newly formed Science and Technology Committee. With over 30 years in the pharmaceutical industry, Crane's expertise spans executive leadership and commercialization. Her role is deemed crucial as Tarsus advances its pipeline, particularly TP-03, aimed at treating Demodex blepharitis. Company executives express confidence in Crane's ability to drive innovation and enhance value during significant upcoming milestones.
Tarsus Pharmaceuticals (TARS) announced positive results from the Saturn-1 trial for TP-03, a treatment for Demodex blepharitis, achieving primary and secondary endpoints. 81% of patients had a clinically meaningful collarette cure. The company also initiated the Saturn-2 trial and the Phase 1 Callisto trial for Lyme disease prevention. Financially, Tarsus reported a net income of $6.3 million for Q2 2021, a significant increase from a net loss of $3.3 million in Q2 2020. Cash and equivalents were $177 million as of June 30, 2021.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced promising results from its Saturn-1 Phase 2b/3 trial for TP-03, targeting Demodex blepharitis. A significant 95% of patients achieved ≤0.5 mites per lash, and 93% improved by at least one collarette grade. Safety analysis showed no clinically significant adverse effects. Additionally, the Titan study revealed 58% of U.S. eye care patients have collarettes, indicating a high prevalence of the condition. Tarsus plans to submit a New Drug Application for TP-03 if upcoming Saturn-2 trial results are favorable.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced that its CEO, Bobak Azamian, will present a corporate update at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 14 at 1:30 PM ET. Tarsus, a late clinical-stage biopharmaceutical company, focuses on unmet medical needs, particularly in eye care. The company is advancing its pipeline, which includes TP-03 for Demodex blepharitis and Meibomian Gland Disease, and TP-05 for Lyme disease prevention. A live webcast of the presentation will be accessible, along with a replay for 90 days.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced that CEO Bobak Azamian will participate in a fireside chat at the Raymond James 2021 Human Health Innovation Conference on June 22 at 12 PM ET. The chat will provide a corporate update on Tarsus's focus on unmet medical needs in eye care and other therapeutic areas. Tarsus is currently conducting clinical trials for its lead product TP-03, targeting Demodex blepharitis and Meibomian Gland Disease, and TP-05, aimed at preventing Lyme disease. The webcast will be available for replay on their official site for 90 days.
Tarsus Pharmaceuticals announced the success of its pivotal Phase 2b/3 Saturn-1 trial for TP-03, demonstrating significant outcomes in treating Demodex blepharitis. The trial met all primary and secondary endpoints, with 81% of patients achieving clinically meaningful collarette cures by day 43. Notably, TP-03 showed a good safety profile, with no serious treatment-related adverse events. This is crucial as Demodex blepharitis affects an estimated 25 million Americans and currently lacks FDA-approved therapies. A conference call to discuss detailed results is scheduled for today at 8:00 a.m. ET.
Tarsus Pharmaceuticals (NASDAQ: TARS) has announced a webcast and conference call scheduled for June 21, 2021, at 8:00 a.m. ET, to discuss results from the Saturn-1 Phase 2b/3 trial of TP-03 for treating Demodex blepharitis. The event will provide insights into the trial outcomes and a corporate update. TP-03 is a key candidate in Tarsus' pipeline, aimed at addressing high unmet needs in eye care. The company is also developing TP-05 for Lyme disease. Full details will be available on Tarsus' website post-event.
Tarsus Pharmaceuticals has initiated the Phase 1 Callisto trial for TP-05, an oral non-vaccine therapeutic aimed at preventing Lyme disease, which affects over 30 million Americans. The trial will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. TP-05 utilizes lotilaner, an anti-parasitic agent that targets ticks, potentially stopping the transmission of the Borrelia bacteria. This trial is pivotal, as there are currently no FDA-approved preventative treatments for Lyme disease.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced that CEO Bobak Azamian and CCO Aziz Mottiwala will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 3:00 PM ET. The presentation will cover the company’s mission to address unmet medical needs through innovative treatments, particularly in eye care. Tarsus is currently advancing its lead product candidate, TP-03, for Demodex blepharitis and Meibomian Gland Disease. A live webcast and replays will be available on their website.
Tarsus Pharmaceuticals has initiated the Saturn-2 Phase 3 trial for TP-03, targeting Demodex blepharitis, with topline data from Saturn-1 expected in July 2021. The FDA has accepted the IND for TP-05, a potential Lyme disease prevention therapy, with a Phase 1 study planned for July. Financially, the company reported a net income of $10.4 million in Q1 2021, a turnaround from a $2.0 million loss in Q1 2020. License fees from a strategic partnership with LianBio generated $33.4 million in revenue. Cash reserves stand at $156.2 million as of March 31, 2021.
FAQ
What is the current stock price of Tarsus Pharmaceuticals (TARS)?
What is the market cap of Tarsus Pharmaceuticals (TARS)?
What is Tarsus Pharmaceuticals' main focus?
What is XDEMVY?
What are the current projects of Tarsus Pharmaceuticals?
What recent achievements has Tarsus Pharmaceuticals accomplished?
Who are the key partners of Tarsus Pharmaceuticals?
Where is Tarsus Pharmaceuticals headquartered?
What is Demodex blepharitis?
What are the side effects of XDEMVY?
What is TP-03?
How does TP-05 work?
